Financials

v3.7.0.1
Consolidated Balance Sheets - USD ($)
Mar. 31, 2017
Dec. 31, 2016
Current Assets    
Cash $ 381,056 $ 182,561
Trade accounts receivable, net 555,708 444,743
Other receivables 2,250
Inventory, net 136,938 160,270
Total Current Assets 1,073,702 789,824
Current Liabilities    
Accounts payable and accrued expenses 562,220 752,930
Derivative liabilities 1,809,890 192,254
Convertible notes payable 100,000
Notes payable, net of discount 25,000 106,365
Total Current Liabilities 2,397,110 1,151,549
Immudyne, Inc. Stockholders' Equity (Deficit)    
Common stock, $0.01 par value; 50,000,000 shares authorized, 40,543,373 and 35,570,157 shares issued, 40,205,573 and 35,245,157 outstanding as of March 31, 2017 and December 31, 2016, respectively 405,433 355,701
Additional paid-in capital 9,363,160 9,070,064
Accumulated (deficit) (10,738,687) (9,693,882)
Equity (970,094) (268,117)
Treasury stock, 337,800 and 325,000 shares, at cost (90,204) (87,053)
Total Immudyne, Inc. Stockholders' (Deficit) (1,060,298) (355,170)
Non-controlling interest (263,110) (6,555)
Total Stockholders' (Deficit) (1,323,408) (361,725)
Total Liabilities and Stockholders' (Deficit) $ 1,073,702 $ 789,824

Source

v3.7.0.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Income Statement [Abstract]    
Net Sales $ 424,462 $ 1,641,028
Cost of Sales 203,356 1,337,942
Gross Profit 221,106 303,086
Operating expenses    
Compensation and related expenses 358,488 240,455
Professional fees 99,632 69,315
Marketing expenses 10,800
General and administrative expenses 127,172 98,412
Total operating expenses 596,092 408,182
Operating (Loss) (374,986) (105,096)
Change in fair value of derivative liability (48,192)
Interest (expense) (649,357) (3,063)
Net (Loss) (1,072,535) (108,159)
Net (loss) attributable to noncontrolling interests (27,730) (46,110)
Net (loss) attributable to Immudyne, Inc. $ (1,044,805) $ (62,049)
Basic and diluted (loss) per share attributable to Immudyne, Inc. $ (0.03) $ 0.00
Average number of common shares outstanding    
Basic 37,581,987 32,010,375
Diluted 37,581,987 32,010,375

Source

v3.7.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES    
Net (loss) attributable to Immudyne, Inc. $ (1,044,805) $ (62,049)
Net (loss) attributable to noncontrolling interests (27,730) (46,110)
Net (loss) (1,072,535) (108,159)
Adjustments to reconcile net (loss) to net cash (used) by operating activities    
Change in fair value of derivative liability 48,192
Bad debt recovery (38,027)
Amortization of debt discount 81,558
Loss on settlement of notes payable 553,222
Stock compensation expense 190,188 38,867
Changes in Assets and Liabilities    
Trade accounts receivable (72,938) (144,902)
Other receivables 2,250
Inventory 23,332 (77,443)
Accounts payable and accrued expenses (188,498) 169,482
Net cash (used) by operating activities (473,256) (122,155)
CASH FLOWS FROM FINANCING ACTIVITIES    
Investment in subsidiary by noncontrolling interest, net 43,378 92,793
Proceeds from notes payable 235,000
Repayment of convertible note payable (100,000)
Repayment of notes payable (151,420)
Sale of common stock and warrants 647,944
Purchase of treasury stock (3,151)
Net cash provided by financing activities 671,751 92,793
Net increase (decrease) in cash 198,495 (29,362)
Cash at beginning of the period 182,561 232,984
Cash at end of the period 381,056 203,622
Supplemental Disclosure of Cash Flow Information    
Cash paid during the period for interest 3,612 3,063
Issuance of company stock for notes and other payables 192,192
Conversion of equity invested in subsidiary to common stock and warrants 272,203
Reclassification of options, warrants and other contracts to derivative liabilities upon issuance $ 1,569,444

Source